Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: even a FDA approval (SAGE) for postpartum depression and a Pfizer (PFE) option to purchase a gene therapy company (Vivet Therapeutics) did not move the risk indicator

March 20, 2019 6:06pm

As the sector spiraled to another two (2) session bottom

What’s the treatment in development for share pricing depression?

Pre-open indications: 5 HIT and 1 MISS

Review the snapshot of the daily ‘workings” of the sector composite of cell and gene therapy companies.

That’s why my “quantamental” blend of styles; must become the “tool” for investors and traders to portfolio enrichment.

Markets and indexes:

The Dow closed down -141.71 points or -0.55% to 25,745.67
The S&P closed down -8.34 points or -0.29% to 2,824.23
The NASDAQ closed up +5.02 points or +0.07% to 7,728.97

Henry’omics:

The Fed forecast no rate hikes in 2019, and that is down from two hikes forecast earlier. The central bank also indicated it intends to end the reduction of its massive $4.2 trillion balance sheet by September. However, the Fed also trimmed its economic growth forecast for 2019 <CNBC>.

Equities were also under pressure after President Trump said U.S. tariffs on Chinese goods could stay on for a long period of time.

Sector equities posted Wednesday’s gains were led by: RGNX (+$2.01 after Tuesday’s +$0.22 and Monday’s +$0.84), RENE.L (+$1.50 after -$1.00 and Monday’s +$6.00), IONS (+$0.60), BLCM (+$0.34) and FIXX (+$0.36)

Crashing on Wednesday was: SAGE (-$3.64), BLUE (-$2.52), BMRN (-$1.48 after Tuesday’s -$1.92 and Monday’s -$1.17), GBT (-$0.81 after Tuesday’s -$0.93), QURE (-$0.64 after Tuesday’s +$0.68 and Monday’s +$2.43) and MESO (-$0.43)

Caladrius Biosciences (CLBS) bounced downward -$0.26 to $3.61 after Tuesday’s +$0.19 and Monday’s decline -$0.18 – ATM picking up the slack – guess not?

Athersys (ATHX) closed up again +$0.02 to $1.57 after Tuesday’s +$0.02 and Monday’s +$0.02. After all these YEARS, where has it been and where is it going having started the year at $1.48 as compared to 3/19/18’s $1.89;

BioLife Solutions (BLFS) closed down again -$0.03 to $20.14 after Tuesday’s-$0.34 and Monday’s +$1.81 – an Icarus flight?

bluebird bio (BLUE) closed down again -$2.52 to $153.58 after Tuesday’s -$0.07 and Monday’s -$1.87 and still feeling the pain of fluctuation and low volume although it saw a low of $138.83 (3/8) having started March at $156.66, February 1 at $134.63 and January 2’s $99.50 – many are still in the money ;

BioTime (NYSE American: BTX) closed up +$0.07 to $1.64 after Tuesday’s slip -$0.06 and Monday’s -$0.10 after their acquisition of Asterias (NYSE American: AST) – their real value has yet to be realized;

Stemline Therapeutics (STML) bounced down -$0.36 to $13.00 after Tuesday’s +$0.46 after closing down Monday -$0.72;

Verastem Oncology (VSTM closed up +$0.17 to $3.58 after Tuesday’s +$0.03 and Monday’s +$0.27; finally we are seeing upside after a bumpy ride since 3/1’s $3.10 after 3/8’s low of $2.79, 2/1’s $3.22 and 1/2’s $3.61;

The Crispers:

CRSP closed down again -$0.14 after Tuesday’s $0.64 to $37.24 after Monday’s -$0.76, followed by …

EDIT closed up +$0.01 to $24.12 after Tuesday’s +$0.14 and Monday’s -$0.32 …

NTLA closing up again +$0.10 to $16.96 after Tuesday’s +$0.15 and Monday’s +$0.02 – they are STILL stuck as trading vehicles;

Mesoblast (MESO) closed down -$0.43 to $4.79 after Tuesday’s +$0.05 and Monday’s +$0.79 – just another rotation fueled by the upside;

Pre-open post, “there is nothing like an FDA approval to ignite the sector, Sage Therapeutics (SAGE) gets FDA approval for Zulresso, a postpartum depression drug; which renews hope that the reward outweighs the risk and time to fruition, exit or least desired – failure.”

The advance/decline line scenario of 45 covered companies:

The open was positive with the A/DL to 22/20, 2 flat and 1 acquired (AST);
The mid-day was negative with an A/DL of 18/28 and 1 flat and 1 acquired;
The close was negative with an A/DL of 18/25 and 1 flat and 1 acquired;

Pre-open indications: 5 HIT and 1 MISS

Sage Therapeutics (SAGE) closed down -$3.64 as many expect a slow roll-out and pricing – miss;
CRISPRS Therapeutics (CRSP) closed down again -$0.14 – hit;
Editas Medicine (EDIT) closing up +$0.01 – hit;
Intellia Therapeutics (NTLA) closing up +$0.10 – hit;
Mesoblast (MESO) closed down -$0.43 – hit;
ReNeuron (RENE.L) closed down -$1.50 – hit;

Tonight’s percentage (%) indicators:

Range of the 18 upside was +0.04% (EDIT) to +13.17% (CUR +$0.088) while the 25 downside ranged from -0.15% (BLFS) to -8.24% (MESO).

Volume stat:

8 out of the 18 upside had higher (than the 3 month average) volume
7 out of the 25 downside experienced greater volume (than the 3 month average)

1 flat – BOLD with 1 acquired: 1 (AST)

The iShares NASDAQ Biotechnology (IBB) indicator:

Wednesday was down -0.59%;
Tuesday was down -0.06%;
Monday was down -0.31% after NOT indicating;
Friday was up +1.07% after indicating a positive +0.26% in the pre-market;
Thursday was down -0.22% after indicating;
Last Wednesday was up +1.31% after indicating;

March sessions:

Wednesday closed NEGATIVE with 25 decliners, 18 advancers, 1 flat and 1 acquired;

Tuesday closed NEGATIVE with 22 decliners, 19 advancers, 3 flats and 1 acquired;

Monday (3/18) closed POSITIVE with 17 decliners, 27 advancers and 1 acquired;

Friday closed POSITIVE with 12 decliners, 32 advancers and 1 flat;

Thursday closed NEGATIVE with 30 decliners, 13 advancers and 2 flats;

Wednesday closed POSITIVE with 12 decliners, 30 advancers and 3 flats;

Tuesday closed POSITIVE with 13 decliners, 30 advancers and 2 flats;

Monday (3/11) closed POSITIVE with 7 decliners, 37 advancers and 1 flat;

Friday closed POSITIVE with 20 decliners, 22 advancers and 3 flats;

Thursday closed POSITIVE with 14 decliners, 29 advancers and 2 flats;

Wednesday closed NEGATIVE with 39 decliners, 5 advancers and 1 flat;

Tuesday (3/4) closed POSITIVE with 17 decliners, 23 advancers and 5 flats;

Monday (3/1) closed NEGATIVE with 24 decliners, 18 advancers and 3 flats;

Friday (3/1) closed POSITIVE with 11 decliners, 32 advancers and 2 flats;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.